Proteintech

Executive Summary

Proteintech is a UK-based biotechnology company established in 2001 that specializes in developing, manufacturing, and selling high-quality research reagents, with a primary focus on antibodies, ELISA kits, and recombinant proteins. The company targets over 13,500 human proteins, and its products are validated for a wide range of applications including Western blot, immunohistochemistry, immunofluorescence, flow cytometry, and ELISA. With over 400,000 citations supporting their use, Proteintech has established itself as a key supplier to the global life sciences research community, offering products from research-use-only (RUO) to clinical-grade (cGMP). The company's extensive catalog and strong citation base position it well to capture growth in both academic and clinical markets. Looking ahead, Proteintech is well positioned to expand its clinical-grade product line and enter new segments such as companion diagnostics. The company's reputation for quality and validation, combined with its already broad product portfolio, provides a solid foundation for revenue growth. While Proteintech is privately held and not publicly traded, its consistent product development and market presence suggest a steady trajectory. The company's focus on high-quality reagents and its large citation footprint indicate a strong competitive moat in the antibody space.

Upcoming Catalysts (preview)

• Q4 2026Launch of new cGMP grade antibodies for immuno-oncology targets70% success
• H2 2026Strategic partnership with a pharmaceutical company for diagnostic kit development50% success
• Q3 2026Expansion of ELISA kit portfolio for neurodegenerative disease biomarkers60% success